BioWorld

Oct. 3, 2002

Elan's Abelcet, Sales Force Go To Enzon For $370M

Enzon Inc. signed an agreement with troubled Irish pharmaceutical company Elan Corp. plc to buy the North American and Japanese rights to Abelcet, Elan's drug for severe fungal infections, for $370 million in cash. (BioWorld Today) Read More

Biosynexus Enters Antibacterial Deal With GSK Unit For $120M

Incurable Prion Diseases Open Crack To Resistance, Diagnosis, Drug Treatment, Gene Therapy

Panel's Advice Is Take The Money, Don't Count On An Open Window

Adherex, Oxiquant To Merge; Four Cancer Drugs In Basket

Deltagen Realignment Reduces Staff 30 Percent, Shuts Facility

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 29, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 28, 2026

Chinese biotechs gain leverage as partners in dealmaking

BioWorld

China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...

Roche identifies new TREM2 agonists

BioWorld Science

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...

Plasticity, properly parsed, provides psychiatric platform

BioWorld

If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...